Alphabet's AI drug discovery spinoff, Isomorphic Labs, affiliated with Google DeepMind and leveraging the AlphaFold protein-folding technology, is preparing to initiate its first human clinical trials for AI-designed medicines later this year. The company, which recently secured $600 million in funding and established partnerships with pharmaceutical giants Novartis and Eli Lilly, aims to revolutionize drug development by making it faster, cheaper, and more precise. The initial trials will focus on AI-designed cancer treatments, including molecules such as Rentosertib, which has shown promise in improving lung function. Isomorphic Labs' president, Colin Murdoch, confirmed the company is "getting very close" to starting these trials. The broader ambition of Isomorphic Labs is to leverage AI to accelerate drug discovery cycles by up to tenfold and ultimately develop therapies capable of addressing a wide range of diseases. This marks a pivotal moment in the integration of artificial intelligence into pharmaceutical research and development, potentially reshaping regulatory frameworks and clinical trial methodologies.